Skip to content | Change text size
 

Dr Jian Li

Image of Dr Jian Li

NHMRC R Douglas Wright Research Fellow
Senior Research Scientist, Facility for Anti-Infective Drug Development and Innovation (FADDI)

BSc Shandong University (China)
MSc Shandong University (China)
PhD University of South Australia

Telephone: +61 3 9903 9702
Fax: +61 3 9903 9629
Email: jian.li@pharm.monash.edu.au

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences

Research interests

  • Pharmacokinetics, pharmacodynamics and toxicodynamics of polymyxins
  • Mechanism of polymyxin resistance in Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae
  • Discovery and development of new antimicrobial agents, in particular novel peptides against polymyxin-resistance Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae
  • Novel anti-pathogenic agents
  • Antimicrobial chemotherapy for infections in patients with cystic fibrosis
  • Integration of pharmacokinetics and pharmacodynamics to assist in antimicrobial development, to reduce resistance development and to optimise efficacy in the clinical use of antimicrobial agents

Representative publications

  1. Zavascki AP, Goldani LZ, Cao GY, Superti SV, Lutz L, Li J, et.al. Pharmacokinetics of intravenous polymyxin B in critically-ill patients. Clinical Infectious Diseases. 2008; 47(10):1298-1304.
  2. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulphonate in pharmaceutical products and solutions for administration to patients. Antimicrobial Agents and Chemotherapy. 2008; 52(9):3047-3051.
  3. Bergen PJ, Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Journal of Antimicrobial Chemotherapy. 2008; 61:636-642.
  4. Zavascki AP, Goldani LZ, Li J, Nation RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. Journal of Antimicrobial Chemotherapy. 2007; 60:1206-1215.
  5. Tan C-H, Li J, Nation RL. Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2007; 51(9):3413-3415.
  6. Li J, Nation RL, Owen RJ, Wong S, Spelman D, Franklin C. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of colistin-resistant strains. Clinical Infectious Diseases. 2007; 45(5):594-598.
  7. Boak LM, Li J, Rayner CR, Nation RL. Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model. Antimicrobial Agents and Chemotherapy. 2007; 51(4):1287-1292.
  8. Owen RJ, Li J, Nation RL, Spelman D. In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates. Journal of Antimicrobial Chemotherapy. 2007; 59:473-477.
  9. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et.al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. The Lancet Infectious Diseases. 2006; 6:589–601.
  10. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D, Tan KE, et.al. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy. 2006; 50(9):2946-2950.
  11. BergenPJ, Li J, Rayner CR and Nation RL Colistin methanesulfonate is an inactive pro-drug of colistin against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2006; 50(6):1953-1958.
  12. Li J, Rayner CR, Nation RL, Deans R, Boots R., Widdecombe N, et.al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrobial Agents and Chemotherapy. 2005; 49(11):4814-4815.
  13. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard, K. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. International Journal of Antimicrobial Agents. 2005; 25:11-26.
  14. Li J, Nation RL, Milne RW, Turnidge JD, Smeaton TC, Coulthard, K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. Journal of Antimicrobial Chemotherapy. 2004; 53:837-840.
  15. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard, K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by High-performance Liquid Chromatography. Antimicrobial Agents and Chemotherapy. 2003; 47(4):1364-1370.
  16. Li J, Coulthard, K., Milne RW, Nation RL, Conway S, Peckham D, et.al. Steady-state pharmacokinetics of intravenous colistin methanesulpho-nate in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy. 2003; 52(6):987-992.
  17. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentin J. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrobial Agents and Chemotherapy. 2002, 46(10):3304-3307.
  18. Li J, Turnidge JD, Milne RW, Nation RL, Coulthard, K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy. 2001; 45(3):781-785.
  19. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson, DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reverse‑phase high-performance liquid chromatography. Journal of Chromatography B, Biomedical Sciences and Applications. 2001; 761(2):167-175.
  20. Li J, Guo, XZ, Li YZ, Zhou L.. Primary study on antitumor metabolites produced by a myxobacterium Corallococcus coralloides 9736.  Chinese Journal of Antibiotics. 1999; 24(4):308-309.

External appointments

  • Member of the International Society of anti-infective Pharmacology
  • Member of the Australian Society for Antimicrobials
  • Member of the American Society for Microbiology
  • Member of the Australasian Pharmaceutical Science Association